Selective deletion of antigen-specific CD8+ T cells by MHC class I tetramers coupled to the type I ribosome-inactivating protein saporin - Wikidata - awgldk - TriplyDB

Selective deletion of antigen-specific CD8+ T cells by MHC class I tetramers coupled to the type I ribosome-inactivating protein saporin

Selective deletion of antigen-specific CD8+ T cells by MHC class I tetramers coupled to the type I ribosome-inactivating protein saporin

http://www.wikidata.org/entity/Q35751049

about

Structure-function study of maize ribosome-inactivating protein: implications for the internal inactivation region and the sole glutamate in the active site Structures and Ribosomal Interaction of Ribosome-Inactivating Proteins An Antigen-Presenting and Apoptosis-Inducing Polymer Microparticle Prolongs Alloskin Graft Survival by Selectively and Markedly Depleting Alloreactive CD8+ T Cells Toxin-coupled MHC class I tetramers can specifically ablate autoreactive CD8+ T cells and delay diabetes in nonobese diabetic mice.Killer artificial antigen-presenting cells: the synthetic embodiment of a 'guided missile'.Increasing inflationary T-cell responses following transient depletion of MCMV-specific memory T cells.Making the most of major histocompatibility complex molecule multimers: applications in type 1 diabetes.The use of peptide-major-histocompatibility-complex multimers in type 1 diabetes mellitus.Targeting Anti-Insulin B Cell Receptors Improves Receptor Editing in Type 1 Diabetes-Prone Mice.Killer artificial antigen-presenting cells: a novel strategy to delete specific T cells.Interrogating the repertoire: broadening the scope of peptide-MHC multimer analysis Tricks with tetramers: how to get the most from multimeric peptide-MHC.Deletion of naïve T cells recognizing the minor histocompatibility antigen HY with toxin-coupled peptide-MHC class I tetramers inhibits cognate CTL responses and alters immunodominance The potential of multimer technologies in type 1 diabetes prediction strategies.Immunotoxins constructed with ribosome-inactivating proteins and their enhancers: a lethal cocktail with tumor specific efficacy.HLA-B*14:02-Restricted Env-Specific CD8+ T-Cell Activity Has Highly Potent Antiviral Efficacy Associated with Immune Control of HIV Infection.Antigen-specific killer polylactic-co-glycolic acid (PLGA) microspheres can prolong alloskin graft survival in a murine model.Saporin-conjugated tetramers identify efficacious anti-HIV CD8+ T-cell specificities.T-cell reconstitution without T-cell immunopathology in two models of T-cell-mediated tissue destruction.A constructed HLA-A2-restricted pMAGE-A1(278-286) tetramer detects specific cytotoxic T lymphocytes in tumour tissues in situ.

P2860

Q24671501-563412C0-99B0-43C8-8B17-573CCBBC7701 Q28072394-BEA96D09-63E5-4318-AF0D-E4E146996139 Q33780582-9260EF74-15F9-420D-AFA7-18F705C5085A Q33844333-F0628FB4-8B01-474F-8A5C-3EC6E7A8BE29 Q34139182-6468AB33-6F69-4238-9C9B-B589826D15AE Q35771566-F12CC827-D5AD-49DB-BED3-748324B53C1E Q36010973-F8D58343-DFE9-4AA9-BAB2-A9643184D7E8 Q36228996-B113514F-3C52-4198-9FFA-9889C4CC04E4 Q36260514-BBC6817A-2DB8-4282-9A5D-42C5762A471A Q36508891-4EEA4F82-6E56-4104-B831-9F26566C1413 Q36975877-41ABC263-EFC3-498E-A6F4-8F16EECAF565 Q37363261-2A3508F3-EFC3-4B20-BF7A-467B88A949D5 Q37403118-0116C343-9737-4187-804E-B69F5DC39055 Q37838895-1266D0D1-DAD7-4511-A093-AD1FCA19C023 Q38262399-1384CD2A-DD0A-4B7A-9A89-3D3E4C059975 Q40054946-3600D6B3-0463-4151-90D2-557F4084B89B Q40975411-1417E3E7-8261-45C4-A75F-A38FD41163D7 Q41919259-47463CDC-EFBF-4DE4-86C4-C71BFE5A0B19 Q43279074-404FFAC1-F065-4FF4-9214-F7479EB96EFB Q54517111-B7D26225-64DC-4721-A7C9-809A436BDF23

P2860

Selective deletion of antigen-specific CD8+ T cells by MHC class I tetramers coupled to the type I ribosome-inactivating protein saporin

http://www.wikidata.org/entity/Q35751049

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Selective deletion of antigen- ...... e-inactivating protein saporin

@ast

Selective deletion of antigen- ...... e-inactivating protein saporin

@en

type

label

Selective deletion of antigen- ...... e-inactivating protein saporin

@ast

Selective deletion of antigen- ...... e-inactivating protein saporin

@en

prefLabel

Selective deletion of antigen- ...... e-inactivating protein saporin

@ast

Selective deletion of antigen- ...... e-inactivating protein saporin

@en

P1433

Q35751049-C81233FE-6454-4735-82DE-4BDA96BF75EB

P1476

Q35751049-528DC4EA-E99A-44C2-AF3B-812A04F2AC32

P2093

Q35751049-483C3FBE-A99E-4D60-B145-B8A17B2CCF7C

Q35751049-48BB5F2D-5880-4828-882E-926B05A6E1EF

Q35751049-58CEAF57-3D41-4C6B-BEE6-26A732DBF41D

Q35751049-8E1C295F-2E13-44BA-9612-852177BC43E1

Q35751049-C2CDD2C7-16F5-4BA4-974F-021A36F98AC3

Q35751049-DA596FC3-9D51-48AE-8883-66FD203884D0

Q35751049-E9A89471-A2E2-49A4-8CCC-FA6AC7AAFF16

P2860

Q35751049-0250C5FF-0355-4DB5-8B9E-F780B4C23417

Q35751049-0A5DCDDA-D488-4F11-B00F-CB444F2182D2

Q35751049-10089B28-F3D9-4F8A-B84F-5BBDCAEED5EE

Q35751049-1589E5AF-95B4-455B-89CC-669C48BDEE5D

Q35751049-25D316F4-F2A8-4E49-91F7-3BF333C8BDFD

Q35751049-282051B1-69F0-498C-BFAE-5F6C49C24064

Q35751049-29FFE579-0A12-4A48-8D45-B75ACAB8769F

Q35751049-2D9B93B4-4999-4854-9344-7DDF3393EA3D

Q35751049-32A032E1-4D87-4E09-89C0-6F434A7F9CCB

Q35751049-36E76576-E863-495B-8047-8C352F23E7D6

P304

Q35751049-CB233C34-05C0-42AA-9A83-C044E3D4297F

P31

Q35751049-747F9279-9197-4349-99F6-5A408DC7937D

P356

Q35751049-8E7BC121-A6C2-4ED4-AE22-94F89118F6A1

P407

Q35751049-9A10476A-D375-4BB3-8D6D-969F99D05BFB

P433

Q35751049-4A1D2778-CC38-4143-9B58-C5CC61BC94CA

P478

Q35751049-F79864B9-5055-4E2B-9DD2-A06BADC9BB17

P577

Q35751049-A12BBD20-8FAC-48BA-B3CD-74524A146F80

P5875

Q35751049-F937B82C-DA2B-43B5-A53F-F26368366CF4

P698

Q35751049-D2744CB7-56E7-4FCA-AD3C-3F1B9F2AA10C

P932

Q35751049-1440C377-3EAE-4717-8D3C-42BD086CC2C1

P356

BLOOD-2006-06-028001

P1433

P1476

Selective deletion of antigen- ...... e-inactivating protein saporin

@en

P2093

Carie Barnes

http://www.w3.org/2001/XMLSchema#string

Edward J Collins

http://www.w3.org/2001/XMLSchema#string

Jeffrey A Frelinger

http://www.w3.org/2001/XMLSchema#string

John M Cullen

http://www.w3.org/2001/XMLSchema#string

Matthew D Woolard

http://www.w3.org/2001/XMLSchema#string

Michael D L Johnson

http://www.w3.org/2001/XMLSchema#string

Paul R Hess

http://www.w3.org/2001/XMLSchema#string

P2860

Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

Phenotypic analysis of antigen-specific T lymphocytes

Interplay between TCR affinity and necessity of coreceptor ligation: high-affinity peptide-MHC/TCR interaction overcomes lack of CD8 engagement

Anti-thymocyte globulin and prednisone immunotherapy of recent onset type 1 diabetes mellitus.

Mononuclear cell infiltration and its relation to the expression of major histocompatibility complex antigens and adhesion molecules in pancreas biopsy specimens from newly diagnosed insulin-dependent diabetes mellitus patients.

Post-transplant malignancy: the role of immunosuppression.

CD8 binding to MHC class I molecules is influenced by T cell maturation and glycosylation.

Targeted deletion of T-cell clones using alpha-emitting suicide MHC tetramers.

Infection in organ-transplant recipients.

P304

3300-3307

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2006-06-028001

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

109

http://www.w3.org/2001/XMLSchema#string

P577

2006-12-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6621456

http://www.w3.org/2001/XMLSchema#string

P698

17179221

http://www.w3.org/2001/XMLSchema#string

P932

1852243

http://www.w3.org/2001/XMLSchema#string